P. Kelly Marcom
- Oncology top 0.2%
- Cancer Research top 0.5%
- Molecular Biology top 5%
- Pulmonary and Respiratory Medicine top 1%
- Radiology, Nuclear Medicine and Imaging top 1%
- Co-authors
- Kimberly BlackwellBeth OvermoyerEric P. WinerHope S. RugoMatthew J. EllisFrankie A. HolmesKathy D. MillerLouis Fehrenbacher
- Topics
- Breast Cancer Treatment Studies (31 papers)BRCA gene mutations in cancer (20 papers)HER2/EGFR in Cancer Research (20 papers)
- Partner nations
- United StatesSingaporeUnited Kingdom
In The Last Decade
P. Kelly Marcom
97 papers receiving 7.9k citations
Hit Papers
Peers
Comparison fields: 5 of 152
- Oncology 5.5k
- Cancer Research 2.7k
- Molecular Biology 1.8k
- Pulmonary and Respiratory Medicine 1.7k
- Radiology, Nuclear Medicine and Imaging 1.1k
Countries citing papers authored by P. Kelly Marcom
This map shows the geographic impact of P. Kelly Marcom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Kelly Marcom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Kelly Marcom more than expected).
Fields of papers citing papers by P. Kelly Marcom
This network shows the impact of papers produced by P. Kelly Marcom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Kelly Marcom. The network helps show where P. Kelly Marcom may publish in the future.
Co-authorship network of co-authors of P. Kelly Marcom
This figure shows the co-authorship network connecting the top 25 collaborators of P. Kelly Marcom. A scholar is included among the top collaborators of P. Kelly Marcom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Kelly Marcom. P. Kelly Marcom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 4 | |
| 2 | 21 | |
| 3 | 31 | |
| 4 | 13 | |
| 5 | 54 | |
| 6 | 15 | |
| 7 | 3 | |
| 8 | 49 | |
| 9 | 109 | |
| 10 | Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markersbreakdown → | 536 |
| 11 | 84 | |
| 12 | 7 | |
| 13 | 65 | |
| 14 | 131 | |
| 15 | 288 | |
| 16 | 123 | |
| 17 | Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomasbreakdown → | 503 |
| 18 | 290 | |
| 19 | 58 | |
| 20 | 96 |
About P. Kelly Marcom
P. Kelly Marcom is a scholar working on Cancer Research, Oncology and Genetics, having authored 98 papers that have together received 8.1k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (31 papers), BRCA gene mutations in cancer (20 papers) and HER2/EGFR in Cancer Research (20 papers). The work is most often cited by research in Oncology (5.5k citations), Cancer Research (2.7k citations) and Pulmonary and Respiratory Medicine (1.7k citations). P. Kelly Marcom has collaborated with scholars based in United States, Singapore and United Kingdom. Frequent co-authors include Kimberly Blackwell, Beth Overmoyer, Eric P. Winer, Hope S. Rugo, Matthew J. Ellis, Frankie A. Holmes, Kathy D. Miller, Louis Fehrenbacher, Melody Cobleigh and Amy P. Sing. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.